These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

151 related articles for article (PubMed ID: 18212618)

  • 1. A pharmacogenetic strategy for immunosuppression based on the CYP3A5 genotype.
    MacPhee IA; Holt DW
    Transplantation; 2008 Jan; 85(2):163-5. PubMed ID: 18212618
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Results of ASERTAA, a Randomized Prospective Crossover Pharmacogenetic Study of Immediate-Release Versus Extended-Release Tacrolimus in African American Kidney Transplant Recipients.
    Trofe-Clark J; Brennan DC; West-Thielke P; Milone MC; Lim MA; Neubauer R; Nigro V; Bloom RD
    Am J Kidney Dis; 2018 Mar; 71(3):315-326. PubMed ID: 29162334
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Tacrolimus pharmacogenetics: the CYP3A5*1 allele predicts low dose-normalized tacrolimus blood concentrations in whites and South Asians.
    Macphee IA; Fredericks S; Mohamed M; Moreton M; Carter ND; Johnston A; Goldberg L; Holt DW
    Transplantation; 2005 Feb; 79(4):499-502. PubMed ID: 15729180
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The influence of pharmacogenetics on the time to achieve target tacrolimus concentrations after kidney transplantation.
    MacPhee IA; Fredericks S; Tai T; Syrris P; Carter ND; Johnston A; Goldberg L; Holt DW
    Am J Transplant; 2004 Jun; 4(6):914-9. PubMed ID: 15147425
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Tacrolimus pharmacogenetics: polymorphisms associated with expression of cytochrome p4503A5 and P-glycoprotein correlate with dose requirement.
    Macphee IA; Fredericks S; Tai T; Syrris P; Carter ND; Johnston A; Goldberg L; Holt DW
    Transplantation; 2002 Dec; 74(11):1486-9. PubMed ID: 12490779
    [TBL] [Abstract][Full Text] [Related]  

  • 6. CYP3A5 polymorphism in Mexican renal transplant recipients and its association with tacrolimus dosing.
    García-Roca P; Medeiros M; Reyes H; Rodríguez-Espino BA; Alberú J; Ortiz L; Vásquez-Perdomo M; Elizondo G; Morales-Buenrostro LE; Mancilla Urrea E; Castañeda-Hernández G
    Arch Med Res; 2012 May; 43(4):283-7. PubMed ID: 22704849
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Influence of CYP3A5 Genetic Polymorphism on Long-Term Renal Function in Chinese Kidney Transplant Recipients Using Limited Sampling Strategy and Abbreviated Area Under the Curve for Tacrolimus Monitoring.
    Cheung CY; Chan KM; Wong YT; Chak WL; Bekers O; van Hooff JP
    Prog Transplant; 2020 Sep; 30(3):249-253. PubMed ID: 32552577
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The effect of CYP3A5 and MDR1 (ABCB1) polymorphisms on cyclosporine and tacrolimus dose requirements and trough blood levels in stable renal transplant patients.
    Haufroid V; Mourad M; Van Kerckhove V; Wawrzyniak J; De Meyer M; Eddour DC; Malaise J; Lison D; Squifflet JP; Wallemacq P
    Pharmacogenetics; 2004 Mar; 14(3):147-54. PubMed ID: 15167702
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Influence of CYP3A5 and MDR1 polymorphisms on tacrolimus concentration in the early stage after renal transplantation.
    Zhang X; Liu ZH; Zheng JM; Chen ZH; Tang Z; Chen JS; Li LS
    Clin Transplant; 2005 Oct; 19(5):638-43. PubMed ID: 16146556
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Impact of the CYP3A5 genotype on the distributions of dose-adjusted trough concentrations and incidence of rejection in Japanese renal transplant recipients receiving different tacrolimus formulations.
    Niioka T; Kagaya H; Saito M; Inoue T; Numakura K; Yamamoto R; Habuchi T; Satoh S; Miura M
    Clin Exp Nephrol; 2017 Oct; 21(5):787-796. PubMed ID: 28271256
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Conversion from Twice-Daily Prograf
    Yau WP; Loh CW; Vathsala A
    Eur J Drug Metab Pharmacokinet; 2019 Aug; 44(4):481-492. PubMed ID: 30471066
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A randomized clinical trial of age and genotype-guided tacrolimus dosing after pediatric solid organ transplantation.
    Min S; Papaz T; Lafreniere-Roula M; Nalli N; Grasemann H; Schwartz SM; Kamath BM; Ng V; Parekh RS; Manlhiot C; Mital S
    Pediatr Transplant; 2018 Nov; 22(7):e13285. PubMed ID: 30178515
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Tacrolimus: review of pharmacokinetics, pharmacodynamics, and pharmacogenetics to facilitate practitioners' understanding and offer strategies for educating patients and promoting adherence.
    Vicari-Christensen M; Repper S; Basile S; Young D
    Prog Transplant; 2009 Sep; 19(3):277-84. PubMed ID: 19813492
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effects of genetic polymorphisms on the pharmacokinetics of calcineurin inhibitors.
    Utecht KN; Hiles JJ; Kolesar J
    Am J Health Syst Pharm; 2006 Dec; 63(23):2340-8. PubMed ID: 17106006
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Use of pharmacogenetics to optimize immunosuppressive therapy.
    Macphee IA
    Ther Drug Monit; 2010 Jun; 32(3):261-4. PubMed ID: 20431509
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Tacrolimus pharmacokinetics and pharmacogenetics: influence of adenosine triphosphate-binding cassette B1 (ABCB1) and cytochrome (CYP) 3A polymorphisms.
    Op den Buijsch RA; Christiaans MH; Stolk LM; de Vries JE; Cheung CY; Undre NA; van Hooff JP; van Dieijen-Visser MP; Bekers O
    Fundam Clin Pharmacol; 2007 Aug; 21(4):427-35. PubMed ID: 17635182
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pharmacogenetics in transplant patients: can it predict pharmacokinetics and pharmacodynamics?
    Burckart GJ; Liu XI
    Ther Drug Monit; 2006 Feb; 28(1):23-30. PubMed ID: 16418689
    [TBL] [Abstract][Full Text] [Related]  

  • 18. No pharmacokinetic interactions between mycophenolic acid and tacrolimus in renal transplant recipients.
    Kagaya H; Miura M; Satoh S; Inoue K; Saito M; Inoue T; Habuchi T; Suzuki T
    J Clin Pharm Ther; 2008 Apr; 33(2):193-201. PubMed ID: 18315786
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Influence of different allelic variants of the CYP3A and ABCB1 genes on the tacrolimus pharmacokinetic profile of Chinese renal transplant recipients.
    Cheung CY; Op den Buijsch RA; Wong KM; Chan HW; Chau KF; Li CS; Leung KT; Kwan TH; de Vrie JE; Wijnen PA; van Dieijen-Visser MP; Bekers O
    Pharmacogenomics; 2006 Jun; 7(4):563-74. PubMed ID: 16753004
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Impact of cytochrome p450 3A5 genetic polymorphism on tacrolimus doses and concentration-to-dose ratio in renal transplant recipients.
    Thervet E; Anglicheau D; King B; Schlageter MH; Cassinat B; Beaune P; Legendre C; Daly AK
    Transplantation; 2003 Oct; 76(8):1233-5. PubMed ID: 14578760
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.